Effect of Oral Combined Berberine and Curcumin Pharmacological Therapy on IBS

Last updated: January 25, 2024
Sponsor: Liaquat University of Medical & Health Sciences
Overall Status: Completed

Phase

N/A

Condition

Gastrointestinal Diseases And Disorders

Colic

Lactose Intolerance

Treatment

A combined supplement of Berberine and Curcumin (Enterophytol® PLUS) alongside standard of care

Clinical Study ID

NCT06187298
LUMHS/UOL-BE/16.12.2023
  • Ages > 18
  • All Genders

Study Summary

Irritable bowel syndrome (IBS) is a prevalent, chronic functional gastrointestinal (GI) disorder, characterized by recurrent abdominal discomfort (pain) associated with altered bowel movements. IBS has a considerable negative impact on people's quality of life (QoL). There is currently no specific treatment available for IBS; most of the therapeutic management is symptomatic. Reported evidence suggest that BBR and CUR can alleviate symptoms of IBS through their multiple pharmacological effects including preventing stress-induced intestinal inflammation and visceral hypersensitivity, reducing bowel motility, and regulating intestinal permeability, gut microme and gut-brain axis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Self-completion of simplified form of the Rome IV IBS diagnostic criteria
  • Had IBS symptoms that appeared before the age of 50
  • Used Enterophytol® PLUS as complementary therapy as two tablets a day for 2-months

Exclusion

Exclusion Criteria:

  • Those with involuntary weight loss
  • Family history of chronic inflammatory bowel disease, colorectal cancer, celiacdisease, rectal discharge, nocturnal symptoms, fever, and abnormalities on clinicalexamination (abdominal mass, signs of anaemia).

Study Design

Total Participants: 146
Treatment Group(s): 1
Primary Treatment: A combined supplement of Berberine and Curcumin (Enterophytol® PLUS) alongside standard of care
Phase:
Study Start date:
August 25, 2020
Estimated Completion Date:
December 15, 2023

Study Description

Aim of the study:

The present clinical study aimed to assess the synergestic therapeutic effect of a combined supplement of standardised extract of BBR and CUR (Enterophytol® PLUS, 200 mg BBR, 49 mg CUR) in the management of IBS.

Method : This was an in real-life setting pragmatic, observational, retrospective, non-controlled and non-randomized clinical trial involving 146 patients with IBS, enrolled in General Practitioner clinics and Pharmacies in Belgium from Aug 2020 to May 2022. The supplement was used as two tablets daily for 2-months, alongside routine IBS care.

Connect with a study center

  • Liaquat University of Medical and Health Sciences

    Jāmshoro,
    Pakistan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.